The Endocrine Disruptor Page HomeSitemap
 

Chemical Safety Office
Evaluation and Licensing Division
Pharmaceutical and Food Safety Bureau
Ministry of Health, Labor and Welfare

Japanese

Last updated date: March 30, 2015
 

Home

 Advisory Committee

   Actions

     Scheme

     Overview

FAQs

Bisphenol A

Reports, etc.

Related reports

Links

Contact

 

 
Actions taken by the Ministry of Health, Labor and Welfare - Overview

  next >>

Introduction
Endocrine disruptors are exogenous substances affecting the endocrine system of organisms, resulting in adverse effects. Except the pharmacology of synthetic hormones, however, no substance has been demonstrated to disrupt the human endocrine system. This situation remains the same since the publication of the Supplement to the Intermediary Report in 2001.
Actions taken according to the Supplement to the Intermediary Report and the remaining major tasks are summarized below.
The action plan itself was also revised according to the results of these actions.

Chapter 1: Results of major actions and future tasks
Section 1: Test scheme

[Results]

  1. (i) In silico screening (prediction by computers), (ii) in vitro screening using cellular and non-cellular systems, and (iii) in vivo screening using ovariectomized animals, juvenile animals and castrated animals were conducted.
  2. Methodologies for the detailed tests are under development for comprehensive examination of the growth process of organisms (embryo - neonate - puberty) and biological reactions (changes in the neural, endocrine, immune and other higher systems).
[Future tasks]
  1. Developing a guideline and evaluation criteria for specific tests
  2. Improving screening techniques for higher precision and comprehensiveness aiming at more precise ordering of substances whose hormonal activities (including those at low doses) can be biologically explained.
  3. For this purpose, adding androgen and thyloid receptors to the screening system currently involving estrogen receptors.
  4. Studying the possibility of pathway screening using the microarray technology
  5. Developing the method of lifelong monitoring of rodents in order to take into account the genesis, development, maturation and aging of the neural, endocrine and immune network, which will be a part of the definitive studies.
  6. Assessing the risk for possible disruptors of human endocrine system to determine appropriate legal or administrational measures such as limitation of application or surveillance, with actual situations of exposure taken into account.

next >>

 

 

About links, copyright, etc. Privacy policy

(C) 2005, 2016 Ministry of Health, Labour and Welfare, All Rights Reserved.